MX2010010465A - Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ. - Google Patents

Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ.

Info

Publication number
MX2010010465A
MX2010010465A MX2010010465A MX2010010465A MX2010010465A MX 2010010465 A MX2010010465 A MX 2010010465A MX 2010010465 A MX2010010465 A MX 2010010465A MX 2010010465 A MX2010010465 A MX 2010010465A MX 2010010465 A MX2010010465 A MX 2010010465A
Authority
MX
Mexico
Prior art keywords
igf
tumor cells
circulating tumor
chr
fish
Prior art date
Application number
MX2010010465A
Other languages
English (en)
Inventor
Brad Foulk
Leon W M M Terstappen
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of MX2010010465A publication Critical patent/MX2010010465A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La presente invención describe los métodos y la composición de las sondas para un ensayo de FISH automatizado de una muestra de sangre que contiene células tumorales circulantes que expresan el gen de IGF-1R. El ensayo proporciona un análisis genético de las posibles células tumorales circulantes que han sido identificadas después de una selección inmunomagnética y la marcación fluorescente. Mediante el uso de sondas únicas sin repeticiones para el locus de IGF-1R y una sonda de referencia del cromosoma 15, se detectaron las líneas celulares que expresaban una cantidad anómala de señales de IGF-1R y Cr 15, que incluía una línea celular con un bajo nivel de amplificación de IGF1R. La capacidad de examinar en forma directa el perfil genético de IGF-1R en las células tumorales circulantes puede proporcionar un medio automatizado para evaluar la enfermedad y la respuesta del paciente al tratamiento.
MX2010010465A 2008-03-25 2009-03-25 Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ. MX2010010465A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3916208P 2008-03-25 2008-03-25
PCT/US2009/038226 WO2009120767A1 (en) 2008-03-25 2009-03-25 A method for detecting igf1r/chr 15 circulating tumor cells using fish

Publications (1)

Publication Number Publication Date
MX2010010465A true MX2010010465A (es) 2010-10-20

Family

ID=41114319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010465A MX2010010465A (es) 2008-03-25 2009-03-25 Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ.

Country Status (12)

Country Link
US (1) US20090258365A1 (es)
EP (1) EP2279266B1 (es)
JP (1) JP2011515109A (es)
KR (1) KR20100131494A (es)
CN (1) CN101978076B (es)
BR (1) BRPI0910038A2 (es)
CA (1) CA2717975A1 (es)
DK (1) DK2279266T3 (es)
ES (1) ES2652467T3 (es)
IL (1) IL207895A (es)
MX (1) MX2010010465A (es)
WO (1) WO2009120767A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8710836B2 (en) 2008-12-10 2014-04-29 Nanomr, Inc. NMR, instrumentation, and flow meter/controller continuously detecting MR signals, from continuously flowing sample material
PE20120415A1 (es) 2008-12-12 2012-05-09 Boehringer Ingelheim Int Anticuerpos anti-igf
CN107422127A (zh) 2009-10-21 2017-12-01 斯克里普斯研究所 用非稀有细胞检测稀有细胞的方法
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US9428547B2 (en) 2010-04-21 2016-08-30 Dna Electronics, Inc. Compositions for isolating a target analyte from a heterogeneous sample
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
EP2833149B1 (en) 2012-03-28 2018-10-03 On-chip Biotechnologies Co., Ltd. Method for detecting degree of malignancy of circulating tumor cell unit, and kit for same
RU2014137125A (ru) * 2012-03-30 2016-05-27 Клариент Дайагностик Сервисез, Инк. Способы формирования изображения биологического образца
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
KR20140147041A (ko) 2013-06-18 2014-12-29 주식회사 엘지화학 셀 포장재료 및 그 제조방법
US10012589B2 (en) 2013-08-16 2018-07-03 The General Hospital Corporation Portable diffraction-based imaging and diagnostic systems and methods
EP3100047B1 (en) 2014-01-27 2021-08-11 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
EP3108246B1 (en) 2014-02-21 2019-10-09 Epic Sciences, Inc. Methods for analyzing rare circulating cells
CA2981543A1 (en) * 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US11149299B2 (en) * 2015-06-25 2021-10-19 Ramesh Vallabhaneni Method and system for multiplex profiling of chromosomes in biological samples using target-specific DNA probes
WO2019082788A1 (ja) * 2017-10-26 2019-05-02 コニカミノルタ株式会社 画像処理装置、合焦位置特定方法及び合焦位置特定プログラム

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475720B1 (en) * 1986-01-16 2002-11-05 The Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6277569B1 (en) * 1990-09-20 2001-08-21 Vysis, Inc. Methods for multiple direct label probe detection of multiple chromosomes or regions thereof by in situ hybridization
US6790366B2 (en) * 1996-06-07 2004-09-14 Immunivest Corporation Magnetic separation apparatus and methods
US6660159B1 (en) * 1996-06-07 2003-12-09 Immunivest Corporation Magnetic separation apparatus and methods
US6890426B2 (en) * 1996-06-07 2005-05-10 Immunivest Corporation Magnetic separation apparatus and methods
GB9716664D0 (en) * 1997-08-06 1997-10-15 Norwegian Inst Of Fisheries & A method of removing nucleic acid contamination reactions
US6063586A (en) * 1997-09-03 2000-05-16 Eye & Ear Foundation Diagnostic protocol
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
US6174681B1 (en) * 1999-03-05 2001-01-16 Mayo Foundation For Medical Education And Research Method and probe set for detecting cancer
WO2000060119A2 (en) 1999-04-01 2000-10-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for detecting cancer cells
WO2000079005A1 (en) * 1999-06-18 2000-12-28 Applied Imaging Corporation High efficiency methods for combined immunocytochemistry and in-situ hybridization
US20030022166A1 (en) * 2001-01-19 2003-01-30 Colin Collins Repeat-free probes for molecular cytogenetics
ES2372007T3 (es) * 2001-02-20 2012-01-12 Vysis, Inc. Métodos y sondas para la detección del cáncer.
AU2002346662A1 (en) * 2001-12-04 2003-06-17 Euregen Llc Methods and compositions for selectively cleaving dna containing duplex acids in a complex nucleic acid mixture
CA2515484C (en) * 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
JP4593557B2 (ja) 2003-02-27 2010-12-08 ベリデックス・リミテッド・ライアビリティ・カンパニー 循環腫瘍細胞（ｃｔｃ）：転移癌患者における増悪までの時間、生存および療法に対する応答の早期評価
US20050059021A1 (en) * 2003-09-15 2005-03-17 Performance Genomics, Inc. Insulin-like growth factor-1 receptor (IGF-1R) polymorphic alleles and use of the same to identify DNA markers for reproductive longevity
US20070037173A1 (en) * 2005-08-12 2007-02-15 Allard Jeffrey W Circulating tumor cells (CTC's): early assessment of time to progression, survival and response to therapy in metastatic cancer patients
JP5457673B2 (ja) * 2005-09-20 2014-04-02 ベリデックス・リミテッド・ライアビリティ・カンパニー ユニーク配列のｄｎａプローブを作製するための方法および組成物、ｄｎａプローブの標識、ならびにこれらプローブの使用
WO2007053142A1 (en) * 2005-11-03 2007-05-10 Immunivest Corporation Agr2 and tff3 regulation in the diagnosis and treatment of cancer
EP2002014A1 (en) * 2006-04-01 2008-12-17 Dako Denmark A/S Method for performing prognoses for high-risk breast cancer patients using top2a gene aberrations
KR101467136B1 (ko) * 2006-06-02 2014-12-01 화이자 프로덕츠 인코포레이티드 순환 종양 세포 분석

Also Published As

Publication number Publication date
BRPI0910038A2 (pt) 2015-12-29
EP2279266B1 (en) 2017-10-11
CN101978076A (zh) 2011-02-16
DK2279266T3 (en) 2017-12-18
ES2652467T3 (es) 2018-02-02
JP2011515109A (ja) 2011-05-19
IL207895A (en) 2015-09-24
CA2717975A1 (en) 2009-10-01
EP2279266A4 (en) 2011-08-10
WO2009120767A1 (en) 2009-10-01
KR20100131494A (ko) 2010-12-15
US20090258365A1 (en) 2009-10-15
CN101978076B (zh) 2016-06-01
EP2279266A1 (en) 2011-02-02
IL207895A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MX2010010465A (es) Metodo para la deteccion de igf1r/chr 15 en celulas tumorales circulantes mediante hibridacion fluorescente in situ.
Siravegna et al. Integrating liquid biopsies into the management of cancer
Goodarzi et al. Irradiation induced foci (IRIF) as a biomarker for radiosensitivity
Krebs et al. Molecular analysis of circulating tumour cells—biology and biomarkers
US20190032139A1 (en) Methods for predicting age and identifying agents that induce or inhibit premature aging
Stutterheim et al. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma
Monteiro et al. Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation
JP2013127477A5 (es)
IN2012DN03156A (es)
IL301804A (en) A system and method for determining a personalized medical intervention for a disease stage
EP2134724A4 (en) REAGENTS FOR DETECTING HYPOCHLOROUS ACID
Shi et al. Fluorescence lifetime imaging of nanoflares for mRNA detection in living cells
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
US20150299796A1 (en) Prediction of treatment response to jak/stat inhibitor
Trautmann et al. Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is functionally essential in myxoid liposarcoma
Lin et al. The SLC36 transporter Pathetic is required for extreme dendrite growth in Drosophila sensory neurons
Ardini et al. ALK inhibitors, a pharmaceutical perspective
Zhang et al. Differential epithelium DNA damage response to ATM and DNA-PK pathway inhibition in human prostate tissue culture
Lin et al. ATP-responsive mitochondrial probes for monitoring metabolic processes of glioma stem cells in a 3D model
McKay et al. Phase II multicenter study of enzalutamide in metastatic castration-resistant prostate cancer to identify mechanisms driving resistance
Zhao et al. A screening platform for glioma growth and invasion using bioluminescence imaging
WO2008029290A3 (en) Identification of cancer stem cells using genetic markers
CN104937412A (zh) 用于鉴定患者特定驱动突变物的方法和系统
WO2015121737A4 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
Apáti et al. The importance of drug transporters in human pluripotent stem cells and in early tissue differentiation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal